BEAM-101
BEAM-101cell therapybase editing of HBG1/2 to reactivate fetal hemoglobin
Sickle Cell Disease
Phase 2
1 program·1 trial·View drug →
DashboardAward20,671$24.47$505.8KAward2,437$22.91$55.8KSell44,900$21.22−$952.6KSell24,195$22.20−$537.1KSell14,395$24.04−$346.1KSell21,803$21.15−$461.1K Diabetes & MetabolismCo-Investigator$398.1K7Diabetes & MetabolismResearch Grant$376.7K5Internal MedicineResearch Grant$260.9K4Internal MedicineResearch Grant$222.8K4EndocrinologyConsulting$64.7K4
BEAMNASDAQ
Beam Therapeutics
Beam Therapeutics Inc. · Cambridge, MA · founded 2017
Beam Therapeutics, based in Cambridge, Massachusetts, develops base-editing medicines — a next-generation gene-editing approach that swaps a single DNA letter without cutting both strands of the helix, aimed at improving precision and reducing off-target effects compared with CRISPR/Cas9. Programs span sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency (AATD), and engineered T-cell therapies for hematologic cancers.
- Lead asset
- BEAM-101 · Ph2 · Sickle Cell Disease
- cell therapy · base editing of HBG1/2 to reactivate fetal hemoglobin
- Pipeline
- 1 drug · 1 program
- 1 Oncology - Heme
- Modalities
- cell therapy×1
FocusGene TherapyRare DiseaseOncology - Heme
$26.00+27.20%1Y
BEAM · daily close · illustrative · 1 catalyst marked
P3 readout+23%
1Y high$28.231Y low$18.29range$9.94(54%)past catalysts
Peers in this space
CRSP$4.4B
CRISPR Therapeutics
Rel.
0.37
Oncology - Hemecell therapy
1 programmatch: sector + modality
EDIT$380M
Editas Medicine
Rel.
0.28
Oncology - Hemecell therapy
1 programmatch: sector + modality
CRBU$240M
Caribou Biosciences
Rel.
0.24
Oncology - Hemecell therapy
1 programmatch: sector + modality
INCY$14.6B
Incyte
Rel.
0.72
Oncology - Hemesmall molecule
1 programmatch: sector
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph21
- Ph30
- Filed0
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
May 30, 2025ReadoutBEAM-101 — Phase 2b Topline Met Primary EndpointPositive+22.6%+31.3%+31.6%
Dec 31, 2024Enroll.BEAM-101 — Pivotal Enrollment CompletePositive+3.4%+4.6%+2.0%
Sep 8, 2023PDUFABEAM-101 — PDUFA — ApprovedPositive+45.3%+22.2%+19.2%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 6 transactions · 6 insiders
Net flow
−$2.3M
Buys
$0
0 txns
Sells
$2.3M
4 txns
Largest
−$952.6K
CFO sell
Net flow per quarter · last 8Q
11 txns · sum −$2.66M
24Q325Q125Q326Q126Q2
buys · $0sells · $2.66M
Insider · roleActionSharesPriceValueDate
M. Kowalski
CEO
Apr 24, 2026
D. Volkov
Director
Apr 21, 2026
P. Kim
CFO
Apr 20, 2026
E. Hassan
Director
Apr 16, 2026
J. Goldstein
EVP
Mar 30, 2026
A. Volkov
Director
Feb 1, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
2 trades · 2 members
Est. net flow
+$2.63M
midpoint · brackets only
Buys
1
Sells
1
Party mix
2 D0 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
D
Sell$250K–$500K~$375KspouseRep. H. Patel
House · IL
Mar 22, 2026
filed +35d
D
Buy$1.00M–$5.00M~$3.00MspouseSen. E. Mendoza
Senate · AZ
Oct 10, 2025
filed +34d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
4 ETFs hold the position
Held by ETFs
$81.2M
aggregate position
Of market cap
3.87%
aggregate ETF share
Top holder
ARKG3.77%
ARK Genomic Revolution ETF
TickerETF · familyThemeNAV% of NAVPosition
ARKGGene editing$1.20B3.77%$45.2M
ARK Genomic Revolution ETF
ARK
ARKKInnovation$5.50B0.27%$14.8M
ARK Innovation ETF
ARK
XBIBroad biotech$7.90B0.18%$14.2M
SPDR S&P Biotech ETF
SPDR
IDNAGenomics$200.0M3.44%$6.9M
iShares Genomics Immunology Healthcare
iShares
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
5 physicians paid · 24 disclosed records
Total 2025+2024
$1.32M
YoY
+18%
Research Grant$661.5KEquity / Ownership$299.8KCo-Investigator$217.7KSpeaking$67.2KConsulting$62.6KTravel & Lodging$14.0KFood & Beverage$377
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Maya Romano
UCSF
Dr. Lin Park
Cedars-Sinai
Dr. Henry Lindberg
Vanderbilt
Dr. Yuki Reyes
Stanford Medicine
Dr. Maya Murphy
University of Michigan
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$257K disclosed · 2 firms engaged
YoY change
+30%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Van Scoyoc Associates$173K
6 quarters active
Invariant$84K
3 quarters active
Top issues lobbied
- Medicare Part B coverage for gene therapies$173K
- CMS reimbursement rates for ultra-rare conditions$42K
- Rare Pediatric Disease Priority Review Voucher$42K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
1 award · 1 agency
Total awarded
$13.6M
across all programs
Active
$13.6M
option periods incl.
Top agency
VA$13.6M
largest active: Veterans Health Administration — Specialty Drug Supply
AgencyTitle · type · award IDStatusValueAwarded → ends
VAactive$13.6MOct 2025→ Apr 2028
Veterans Health Administration — Specialty Drug Supply
Contract · VA-62320118
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
6 granted · 4 pending
Total in portfolio
10
Granted in last 12mo
2
Expiring < 2yr
0
Nearest expiry
Apr 2030
Patent #Title · inventor · drugTypeStatus · filedExpiry
10,057,204Process
Continuous manufacturing process for BEAM-101
R. Tanaka + 4 · BEAM-101
grantedfiled Apr 2025
exp. Apr 2045
19.0y left
11,862,845Composition of Matter
Modified RNA constructs and methods of use thereof BEAM-101
B. Tanaka · BEAM-101
grantedfiled Apr 2024
exp. Apr 2044
18.0y left
US 2025/8955160 A1Process
Purification methods for BEAM-101
J. Park + 1 · BEAM-101
pendingfiled Apr 2025
in prosecution
US 2024/7144590 A1Method of Use
Methods of treating advanced disease using BEAM-101
F. Park + 1 · BEAM-101
pendingfiled Apr 2024
in prosecution
11,388,814Formulation
Pre-filled syringe formulations comprising BEAM-101
M. Goldstein + 1 · BEAM-101
grantedfiled Apr 2021
exp. Apr 2041
15.0y left
US 2023/1378188 A1Formulation
Pre-filled syringe formulations comprising BEAM-101
M. Hoffman + 3 · BEAM-101
pendingfiled Apr 2023
in prosecution
US 2017/3198896 A1Formulation
Stable lyophilized formulations of BEAM-101
K. Romano + 2 · BEAM-101
pendingfiled Apr 2017
in prosecution
12,291,816Formulation
Sustained-release oral compositions of BEAM-101
B. Park + 2 · BEAM-101
grantedfiled Apr 2013
exp. Apr 2033
7.0y left
showing 8 of 10 · full portfolio available on Pro
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
10 items from 5 categories
regulatory4partnership3analyst1corporate1clinical1
just now
BEAM announces strategic collaboration in rare disease
Business Wire·partnership
just now
Analyst initiates coverage of BEAM with Buy rating
Reuters·analyst
4d ago
BEAM expands manufacturing capacity at lead facility
Business Wire·corporate
22d ago
BEAM receives Orphan Drug Designation for BEAM-101
Endpoints News$·regulatory
1mo ago
BEAM expands co-development partnership for next-gen pipeline
Business Wire·partnership
2mo ago
BEAM completes enrollment in BEAM-101 Phase 2 trial
PR Newswire·clinical
2mo ago
EMA validates BEAM's Marketing Authorization Application for BEAM-101
Endpoints News$·regulatory
2mo ago
FDA accepts BEAM's NDA for BEAM-101; PDUFA date set
FierceBiotech·regulatory
2mo ago
BEAM enters licensing agreement with major pharma for BEAM-101
PR Newswire·partnership
2mo ago
FDA grants Fast Track Designation to BEAM's BEAM-101 program
PR Newswire·regulatory
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$26.00
Open
$25.87
Day Δ
+0.13
+0.50%
Day range
$25.73 – $26.14
52W range
$18.29 – $28.23
Avg daily volume
517K
Valuation & ownership
Enterprise value
$1.4B
Shares out
80.77M
Float
74.31M
Insider %
6.07%
Institutional %
31.07%
Beta
1.07
vs SPY · 52w
Balance sheet & burn
Cash + invest
$1.2B
Total debt
$7M
Debt / equity
2.07
Cash burn / Q
$92M
R&D spend TTM
$386M
31% of cash
ATM available
None
no active facility
Earnings
EPS latest
$-0.72
EPS Δ vs prior
+0.07
EPS estimate
$-0.75
next quarter
EPS prior
$-0.79
Next earnings
May 10, 2026
Rev guidance
$25M